Literature DB >> 24371594

Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.

Deanna Teoh1, John S Won2, Robert Eisberg3, Kimberly Nolte1, Angeles Alvarez Secord1.   

Abstract

► Bevacizumab may increase the risk of mucosal ulceration and subsequent bone necrosis. ► Patients receiving bevacizumab should be closely monitored for dental symptoms.

Entities:  

Keywords:  Bevacizumab; Ovarian cancer

Year:  2011        PMID： 24371594      PMCID： PMC3857685          DOI： 10.1016/j.gynor.2011.09.001

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  4 in total

1.  Occurrence of torus palatinus and mandibularis among women of different ethnic groups.

Authors:  A A Chohayeb; A R Volpe
Journal:  Am J Dent       Date:  2001-10       Impact factor: 1.522

2.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

3.  Oral health considerations in older women receiving oral bisphosphonate therapy.

Authors:  Joan C Lo; Felice O'Ryan; Jingrong Yang; Mohammad K Hararah; Joel R Gonzalez; Nancy Gordon; Paula Silver; Alice Ansfield; Benjamin Wang; Alan S Go
Journal:  J Am Geriatr Soc       Date:  2011-05-03       Impact factor: 5.562

4.  Buccal and palatal exostoses: prevalence and concurrence with tori.

Authors:  A Jainkittivong; R P Langlais
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2000-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.